Schwartz, Gregory GGregory GSchwartzSzarek, MichaelMichaelSzarekBittner, Vera AVera ABittnerDiaz, RafaelRafaelDiazGoodman, Shaun GShaun GGoodmanJukema, J WouterJ WouterJukemaLandmesser, UlfUlfLandmesserLópez-Jaramillo, PatricioPatricioLópez-JaramilloManvelian, GarenGarenManvelianPordy, RobertRobertPordyScemama, MichelMichelScemamaSinnaeve, Peter RPeter RSinnaeveWhite, Harvey DHarvey DWhiteGabriel Steg, PhPhGabriel StegJUEY-JEN HWANG2024-03-292024-03-292021-08-0307351097https://www.scopus.com/record/display.uri?eid=2-s2.0-85110291084&doi=10.1016%2fj.jacc.2021.04.102&origin=inward&txGid=fa0a0f1033879bc6a1a9f1dcd4e0c6a8https://scholars.lib.ntu.edu.tw/handle/123456789/641634Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.enPCSK9 inhibitor; acute coronary syndrome; lipoprotein(a); low-density lipoprotein cholesteroljournal article10.1016/j.jacc.2021.04.102343258312-s2.0-85110291084